Progress in developing amphiphilic cyclodextrin-based nanodevices for drug delivery

Current Topics in Medicinal Chemistry

Volumn 14, Issue 4, 2014, Pages 526-541

  Yaméogo, Josias B G ^a,c   Gèze, Annabelle ^a   Choisnard, Luc ^a   Putaux, Jean Luc ^b   Semdé, Rasmané ^c   Wouessidjewe, Denis ^a  

^a Centre National de la Recherche Scientifique   (France)

^b CENTRE DE RECHERCHES SUR LES MACROMOLÉCULES VÉGÉTALES CERMAV CNRS   (France)

^c UNIVERSITÉ DE OUAGADOUGOU   (Burkina Faso)

Author keywords

Amphiphilic cyclodextrins; Bioevaluation; Characterization; Drug delivery; Nanoparticles; Synthesis

Indexed keywords

ACRIDONE DERIVATIVE; ALPHA CYCLODEXTRIN; AMPHOPHILE; AMPHOTERICIN B; ARTEMISININ; BENZYL BENZOATE; BETA CYCLODEXTRIN; BIFONAZOLE; CAMPTOTHECIN; CLOTRIMAZOLE; CYCLODEXTRIN; DIAZEPAM; DOCETAXEL; DOXORUBICIN; GAMMA CYCLODEXTRIN; GENISTEIN; HYDROCORTISONE; INDOMETACIN; INSULIN; IRINOTECAN; METRONIDAZOLE; NANOCAPSULE; NANOCARRIER; NANOPARTICLE; NANOSPHERE; NIMODIPINE; PACLITAXEL; PROGESTERONE; TAMOXIFEN; TESTOSTERONE; UNINDEXED DRUG;

CARBON NUCLEAR MAGNETIC RESONANCE; CYTOTOXICITY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG RELEASE; ELECTROSPRAY MASS SPECTROMETRY; ENZYME SPECIFICITY; HUMAN; INFRARED SPECTROSCOPY; LIGHT SCATTERING; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NANODEVICE; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; REVIEW; TRANSMISSION ELECTRON MICROSCOPY; X RAY ANALYSIS;

CYCLODEXTRINS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; NANOPARTICLES; PHARMACEUTICAL PREPARATIONS;

EID: 84894047943     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026613666131219125135     Document Type: Review

References (132)

1. Leemhuis, H.; Kelly, R.M.; Dijkhuizen, L. Engineering of cyclodextrin glucanotransferases and the impact for biotechnological applications. Appl. Micro.biol. Biotechnol., 2010, 85, 823-835.
2. Davis, M.E.; Brewster, M.E. Cyclodextrin-based pharmaceutics: past, present and future. Nat. Rev. Drug Discov., 2004, 3, 1023-1035.
3. Rajesweri, C.; Alka, A.; Javed, A.; Khar, R.K. Cyclodextrins in drug delivery: an updated review. AAPS Pharm.Sci.Tech., 2005, 6, 329-357.
4. Shimpi, S.; Chauhan, B.; Shimpi, P. Cyclodextrins: application in different routes of drug administration. Acta. Pharm., 2005, 55, 139-156.
5. Salustio, P.J.; Pontes, P.; Conduto, C.; Sanches I.; Carvalho, C.; Arrais, J.; Cabral Marques, H. Advanced Technologies for oral Controlled Release: cyclodextrins for oral controlled Release, AAPS Pharm.Sci.Tech., 2011, 12 (4), 1276-1292.
6. Katageri, A.R.; Sheikh, M.A. Cyclodextrin a gift to pharmaceutical world review. Int. Res. J. Pharm., 2012, 3(1), 52-56.
7. Loftsson, T.; Brewster, M.E. Cyclodextrins as functional excipients: methods to enhance complexation efficiency. J. Pharm. Sci., 2012, 101(9), 3019-3032.
8. Devil, N.K.D.; Rani, A.P.; Muneer, J.M.; Kumar, K.S.; Kaushik, J.; Sowjanya, V. Cyclodextrins in pharmacy-an overview, Pharmacophore, 2010, 1(3), 155-165.
9. Takahashi A.I.; Veiga, F.J.B.; Ferraz H.G. A literature review of cyclodextrins inclusion complexes characterization - part I: phase solubility diagram, dissolution, and scanning electron microscopy. Int. J. Pharm. Sci. Rev. Res., 2012, 12(1), 1-7.
10. Takahashi A.I.; Veiga, F.J.B.; Ferraz H.G. A literature review of cyclodextrins inclusion complexes characterization - part II: X- Ray diffraction, infrared spectroscopy and nuclear magnetic resonance. Int. J. Pharm. Sci. Rev. Res., 2012, 12(1), 8-15.
11. Takahashi A.I.; Veiga, F.J.B.; Ferraz H.G. A literature review of cyclodextrins inclusion complexes characterization - part III: differential scanning calorimetry and thermogravimetry. Int. J. Pharm. Sci. Rev. Res., 2012, 12(1), 16-20.
12. Loftsson, T.; Duchêne, D. Cyclodextrins and their pharmaceutical applications. Int. J. Pharm., 2007, 329, 1-11.
13. Messner, M.; Kurkov, S.V.; Jansook, P.; Loftsson, T. Self- assembled cyclodextrin aggregates and nanoparticles. Int. J. Pharm., 2010, 387, 199-208.
14. Bonini, M.; Rossi, S.; Karlsson, G.; Almgren, M.; Lo Nostro, P.; Baglioni, P. Self-assembly of -cyclodextrin in water. Part 1: Yaméogo et al. Cryo-TEM and Dynamic and Static Light Scattering, Langmuir, 2006, 22, 1478-1484.
15. Fülöp, Z.; Kurkov, S.V.; Nielsen T.T.; Larsen, K.L.; Loftsson, T. Self-assembly of cyclodextrins: formation of cyclodextrin polymer based nanoparticles. J. Drug Del. Sci. Tech., 2012, 22(3), 215-222.
16. Duchêne, D.; Ponchel, G.; Wouessidjewe, D. Cyclodextrins in targeting, Application to nanoparticles. Adv. Drug Deliv. Rev., 1999, 36, 29-40.
17. Kawabata, Y.; Matsumoto, M.; Tanaka, M.; Takahashi, H.; Irinatsu, Y.; Tamara, S.; Tagaki, W.; Nakahara, H.; Fukuda, K. Formation and deposition of monolayers of amphiphilic -cyclodextrin derivatives. Chem. Lett., 1986, 11, 1933-1934.
18. Wenz, G. Synthesis and characterization of some lipophilic per(2,6-di-O-alkyl) cyclomalto-oligosaccharides. Carbohydr. Res., 1991, 214, 257-265.
19. Canceill, J.; Jullien, L.; Lacombe, L.; Lehn, J.M. Channel-type molecular structures. Part 2. Synthesis of bouquet-shaped molecules based on a -cyclodextrin core. Helv. Chim. Acta, 1992, 75, 791-812.
20. Zhang, P.; Ling C.C.; Coleman, A.W.; Parrot-Lopez, H.; Galons, H. Formation of amphiphilic cyclodextrins via hydrophobic esterification at the secondary hydroxyl face. Tetrahedron Lett., 1991, 32, 2769-2770.
21. Lesieur, S.; Charon, D.; Lesieur, P.; Ringard-Lefebvre, C.; Muguet, V.; Duchêne, D.; Wouessidjewe, D. Phase behavior of fully hydrated DMPC-amphiphilic cyclodextrin systems. Chem. Phys. Lipids, 2000, 106, 127-144.
22. Tchoreloff, P.; Boissonnade, M.M.; Coleman, A.W.; Bazskin, A. Amphiphilic monolayers of insoluble cyclodextrins at the water/air interface. Surface pressure and surface potential studies. Langmuir, 1995, 11, 191-196.
23. Choisnard, L.; Gèze, A.; Putaux, J.L.; Wong, Y.S.; Wouessidjewe, D. Nanoparticles of -cyclodextrin esters obtained by self- assembling of biotransesterified cyclodextrins. Biomacromolecules, 2006, 7, 515-520.
24. Choisnard, L.; Gèze, A.; Yaméogo, B.G.J.; Putaux, J.L.; Wouessidjewe, D. Miscellaneous nanoaggregates made of -Cyclodextrins esters synthesised by an enzymatic pathway. Int. J. Pharm., 2007, 344, 26-32.
25. Mendez-Ardoy, A.; Gomez-Garcia, M.; Gèze, A.; Putaux, J.L.;Wouessidjewe, D.; Ortiz Mellet, C.; Defaye, J.; Garcia Fernandez, J.M.; Benito, J.M. Monodisperse nanoparticles from self- assembling amphiphilic cyclodextrins: modulable tools for the encapsulation and controlled release of pharmaceuticals. Med. Chem., 2012, 8, 524-532.
26. Diakur, J.; Zuo, Z.; Wiebe, L.I. Synthesis and drug complexation studies with -cyclodextrins fluorinated on the primary face. J. Carbohydr. Chem., 1999, 18, 209-223.
27. Granger, C.E.; Felix, C.P.; Parrot-Lopez, H.P.; Langlois, B.R. Fluorine containing -cyclodextrin: a new class of amphiphilic carriers. Tetrahedron Lett., 2000, 41, 9257-9260.
28. Péroche, S.; Parrot-Lopez, H. Novel fluorinated amphiphilic cyclodextrin derivatives: Synthesis of mono, di- and heptakis-(6-deoxy- 6-perfluoroalkylthio)--cyclodextrins. Tetrahedron Lett., 2002, 44, 241-245.
29. Bertino-Ghera, B.; Perret, F.; Fenet, B.; Parrot-Lopez, H. Control of regioselectivity for new amphiphilic cyclodextrins: Synthesis of di- and tetra (6-deoxy-6-alkylthio) and 6- (perfluoroalkylpropanethio)- -cyclodextrin derivatives. J. Org. Chem., 2008, 73, 7317-7326.
30. Skiba, M.; Skiba-Lahiani, M.; Arnaud, P. Design of nanocapsules based on novel fluorophilic cyclodextrin derivatives and their potential role in oxygen delivery. J. Incl. Phenom. Macrocycl. Chem., 2002, 44, 151-154.
31. Falvey, P.; Lim, W.C.; Darcy, R.; Revermann, T.; Karst, U.; Giesbers, M.; Marcelis, A.T.M.; Lazar, A.; Coleman, A.W.; Reinhoudt, D.N.; Ravoo, B.J. Bilayer vesicles of amphiphilic cyclodextrins: host membranes that recognize guest molecules. Chem. Eur. J., 2005, 11, 1171-1780.
32. Kauscher U.; Stuart, M.C.A.; Drucker, P.; Galla, H-J.; Ravoo, B.J. Incorporation of amphiphilic cyclodextrins into liposomes as artificial receptor units. Langmuir, 2013, 29, 7377-7383.
33. Mazzaglia, A.; Valerio, A.; Villari, V.; Rencurosi, A.; Lay, L.; Spadaro, S.; Micali, N. Probing specific protein recognition by size-controlled glycosylated cyclodextrin nanoassemblies. New J. Chem., 2006, 30, 1662-1668.
34. McNicholas, S.; Rencurosi, A.; Lay, L.; Mazzaglia, A.; Sturiale, L.; Perez, M.; Darcy, R. Amphiphilic N-Glycosyl-thiocarbamoyl cyclodextrins: synthesis, self-assembly and fluorimetry recognition by Lens culinaris lectin. Biomacromolecules, 2007, 8, 1851-1857.
35. Salameh, A.; Lazar, A.N.; Coleman, A.W.; Parrot-Lopez, H. Synthesis and interfacial properties of amphiphilic -cyclodextrins and their substitution at the O-6 position with a mono bio-recognizable galactosyl antenna. Tetrahedron, 2005, 61, 8740-8745.
36. Defaye, J.; Balbuena, P.; Benito, J.M.; Diaz-Moscoso, A.; Di Giorgio, C.; Garcia Fernandez, J.M.; Gèze, A.; Gomez-Garcia, M.; Ortiz-Mellet, C.; Vierling, P.; Wouessidjewe, D. Preparation of nanosphere amphiphilic cyclodextrin derivatives as biological transporters. PCT Int. Appl. 2008, WO 2008009831, WO 2007-FR1259 20070720.
37. Bellanger, N.; Perly, B. NMR investigation of the conformation of new cyclodextrin-based amphiphilic transporters for hydrophobic drugs: molecular lollipops. J. Mol. Struct., 1992, 273, 215-226.
38. Lin, J.; Creminon, C.; Perly, B.; Djedaïni-Pilard, F. New amphiphilic derivatives of cyclodextrins for the purpose of insertion in biological membranes: the cup and ball molecules. J. Chem. Soc., Perkin Trans., 1998, 2, 2639-2646.
39. Auzély-Velty, R.; Perly, B.; Taché, O.; Zemb, T.; Dalbiez, J.P.; Djedaïni-Pilard, F. Cholesteryl-cyclodextrins: synthesis and insertion into phospholipid membranes. Carbohydr. Res., 1999, 318, 82-90.
40. Auzély-Velty, R.; Djedaïni-Pilard, F.; Désert, S.; Perly, B.; Zemb, T. Micellization of hydrophobically modified cyclodextrins. 1. Micellar structure. Langmuir, 2000, 16, 3727-3734.
41. Auzély-Velty, R.; Péan, C.; Djedaïni-Pilard, F.; Zemb, T.; Perly, B. Micellization of hydrophobically modified cyclodextrins. 2. Inclusion of guest molecules. Langmuir, 2001, 17, 504-510.
42. Moutard, S.; Perly, B.; Gode, P.; Demaillly, G.; Djedaïni-Pilard, F. Novel glycolipids based on cyclodextrins. J. Incl. Phenom. Macrocycl. Chem., 2002, 44, 317-322.
43. Angelova, A.; Fajolles, C.; Hocquelet, C.; Djedaïni-Pilard, F.; Lesieur, S.; Bonnet, V.; Perly, B.; Lebas, G.; Mauclaire, L. Physicochemical investigation of asymmetrical peptidolipidyl- cyclodextrins. J. Colloid Interf. Sci., 2008, 322, 304-314.
44. Kraus, T.; Budesinsky, M.; Zavada, J. General approach to the synthesis of persubstituted hydrophilic and amphiphilic - cyclodextrin derivatives. J. Org. Chem., 2001, 66, 4595-4600.
45. Dubes, A.; Bouchu, D.; Lamartine, R.; Parrot-Lopez, H. An efficient regio-specific synthetic route to multiply substituted acyl- sulfated -cyclodextrins. Tetrahedron Lett., 2001, 42, 9147-9151.
46. Dubes, A.; Degobert, G.; Fessi, H.; Parrot-Lopez, H. Synthesis and characterisation of sulfated amphiphilic -, - and -cyclodextrins: application to the complexation of acyclovir. Carbohydr. Res., 2003, 338, 2185-2193.
47. Abdelwahed, W.; Degobert, G.; Dubes, A.; Parrot-Lopez, H.; Fessi, H. Sulfated and non-sulfated amphiphilic -cyclodextrins: Impart of their structural properties on the physicochemical properties of nanoparticles. Int. J. Pharm., 2008, 351, 289-295.
48. Donohue, R.; Mazzaglia, A.; Ravoo, B.J.; Darcy, R. Cationic - cyclodextrin bilayer vesicles. Chem. Commun., 2002, 23, 2864-2865.
49. Diaz-Moscoso, A.; Balbuena, P.; Gomez-Garcia, M.; Ortiz-Mellet, C.; Benito, J.M.; Le Gourriérec, L.; Di Giorgio, C.; Vierling, P.; Mazzaglia, A.; Micali, N.; Defaye, J.; García Fernández, J.M. Rational design of cationic cyclooligosaccharides as efficient gene delivery systems. Chem. Commun., 2008, 17, 2001-2003.
50. Ortiz-Mellet, C.; García Fernández, J.M.; Benito, J.M. Cyclodextrins-based gene delivery systems. Chem. Soc. Rev., 2011, 40, 1586-1608.
51. Cryan, S.A.; Donohue, R.; Ravoo, B.J.; Darcy, R.; O'Driscoll, C.M. Cationic amphiphilic cyclodextrins as gene delivery vectors. J. Drug Del. Tech., 2004, 14, 57-62.
52. Cryan, S.A.; Holohan, A.; Donohue, R.; Darcy, R.; O'Driscoll, C.M. Cell transfection with polycationic cyclodextrin vectors. Eur. J. Pharm. Sci., 2004, 21, 625-633.
53. Kandoth, N.; Vittorino, E.; Sciortino, M.T.; Parisi, T.; Colao, I.; Mazzaglia, A.; Sortino, S. A cyclodextrin-based nanoassembly with bimodal photodynamic action. Chem. A Eur. J., 2012, 18(6), 1684-1690.
54. Mazzaglia, A.; Valerio, A.; Micali, N.; Villari, V.; Quaglia, F.; Castriciano, M.A.; Scolaro, L.M.; Giuffre, M.; Siracunaso, G.; Sciortino, T. Effective cell uptake of nanoassemblies of a fluores- cent amphiphilic cyclodextrin and an anionic porphyrin. Chem. Commun., 2011, 47, 9140-9142.
55. Ferro, S.; Jori, G.; Sortino, S.; Stancanelli, R.; Nikolov, P.; Tognon, G.; Riccheli, F.; Mazzaglia, A. Inclusion of 5-[4-(1- Dodecanoylpyridinium)]-10,15,20-triphenylporphine in supramolecular aggregates of cationic amphiphilic cyclodextrins: physicochemical characterization of the complexes and strengthening of the antimicrobial photosensitizing activity. Biomacro- molecules, 2009, 10, 2592-2600.
56. Roux, M.; Perly, B.; Djedaïni-Pilard, F. Self-assemblies of amphiphilic cyclodextrins. Eur. Biophys. J., 2007, 36, 861-867.
57. Sallas, F.; Darcy, R. Amphiphilic cyclodextrins - Advanced in synthesis and supramolecular chemistry. Eur. J. Org. Chem., 2008, 6, 957-969.
58. Bilensoy, E. Nanoparticulate delivery systems based on amphiphilic cyclodextrins. J. Biomed. Nanotechnol., 2008, 4, 293-303.
59. Bilensoy, E.; Hincal, A.A. Recent advances and future directions in amphiphilic cyclodextrin nanoparticles. Expert Opin. Drug Deliv., 2009, 6, 1161-1173.
60. Parrot-Lopez, H.; Perret, F.; Bertino-Ghera, B. Amphiphilic cyclodextrins and their applications. Preparation of nanoparticles based on amphiphilic cyclodextrins for biomedical application. Ann. Pharm. Fr., 2010, 68, 12-26.
61. Mazzaglia, A.; Sciortino, M.T.; Kandoth, N.; Sortino, S. Cyclodextrin-based nanosconstructs for photoactivated therapies, J. Drug Del. Sci. Tech., 2012, 22 (3), 235-242.
62. Frank, D.W.; Gray, J.E.; Weaver, R.N. Cyclodextrin nephrosis in the rat. Am. J. Pathol., 1976, 83, 367-382.
63. Villari, V.; Mazzaglia, A.; Darcy, R.; O'Driscoll, C.M.; Micali, N. Nanostructures of cationic amphiphilic cyclodextrin complexes with DNA. Biomacromolecules, 2013, 14, 811-817.
64. Memisoglu, E.; Bochot, A.; Sen, M.; Charon, D.; Duchêne, D.; Hincal, A.A. Amphiphilic -cyclodextrins modified on primary face: Synthesis, characterization and evaluation of their potential as novel excipients in the preparation of nanocapsules. J. Pharm. Sci., 2002, 91, 1214-1224.
65. Gallois-Montbrun, D.; Thiebault, N.; Moreau, V.; Lebas, G.; Archambault, J.C.; Lesieur, S.; Djedaïni-Pilard, F. Direct synthesis of novel amphiphilic cyclodextrin. J. Incl. Phenom. Macrocycl., 2007, 57, 131-135.
66. Stancanelli R.; Lojkner L.D.; Larsen K.L.; Guardo, M.; Cannava, C.; Tommasini, S.; Ventura, C.A.; Calabro, M.L.; Micali, N.; Villari, V.; Mazzaglia, A. Structural and spectroscopic features of lutein/butanoyl-B-cyclodextrin. J. Pharm. Biomed. Anal., 2012, 71, 214-218.
67. Gèze, A.; Aous, S.; Baussanne, I.; Putaux, J.L.; Defaye, J.; Woues- sidjewe, D. Influence of chemical structure of amphiphilic - cyclodextrins on their ability to form stable nanoparticles. Int. J. Pharm., 2002, 242, 301-305.
68. Pedersen, N.R.; Kristensen, J.B.; Bauw, G.; Ravoo, J.; Darcy, R.; Larsen, K.L.; Pedersen, L.H. Thermolysin catalyzes the synthesis of cyclodextrin esters in DMSO, Tetrahedron: Asymmetry, 2005, 16, 615-622.
69. Perez-Victoria, I.; Morales, J.C. Regioselectivity in acylation of oligosaccharides catalysed by the metalloprotease thermolysin. Tetrahedron, 2006, 62, 2361-2369.
70. Choisnard, L.; Gèze, A.; Vanharverbeke, C.; Yaméogo, J.B.G.; Putaux, J.-L.; Brasme, B.; Julien, L.; Boullanger, S.; Elfakir, C.; Wouessidjewe, D. Physicochemical characterization of -, - and -cyclodextrins bioesterified with decanoate chains used as building blocks of colloidal nanoparticles. Biomacromolecules, 2011, 12, 3031-3038.
71. Gèze, A.; Choisnard, L.; Putaux, J.L.; Wouessidjewe, D. Colloidal systems made of biotransesterified cyclodextrins grafted with C10 alkyl chains. Mater. Sci. Eng. C, 2009, 29, 458-462.
72. Kieken, F.; West, C.; Keddadouche, K.; Elfakir, C.; Choisnard, L.; Gèze, A.; Wouessidjewe, D. Characterization of complex amphiphilic cyclodextrin mixtures by high-performance liquid chromatography and mass spectrometry. J. Chromatogr. A., 2008, 1189, 385-391.
73. Lombardo, D.; Longo, A.; Darcy, R.; Mazzaglia, A. Structural properties of non-ionic cyclodextrin colloids in water. Langmuir, 2004, 20, 1057-1064.
74. Ravoo, B.J.; Darcy, R. Cyclodextrin bilayer vesicles. Angew. Chem. Int. Ed., 2000, 39, 4324-4326.
75. Micali, N.; Villarir, V.; Mazzaglia, A.; Monsu Scolaro, L.; Valerio, A.; Rencurosi, A.; Lay, L. Cyclodextrin nanoaggregates and their assembly with protein: a spectroscopic investigation. Nanotechnology, 2006, 17, 3239-3244.
76. Stancanelli, R.; Guardo, M.; Cannava, C.; Guglielmo, C.; Ficarra, G.; Villari, V.; Micali, N.; Mazzaglia, A. Amphiphilic cyclodextrins as nanocarriers of genistein: a spectroscopic investigation pointing out the structural properties of the host/drug complex system. J. Pharm. Sci., 2010, 99, 3141-3149.
77. Fessi, H.; Devissaguet, J.P.; Thies, C. Process for the preparation of dispersible colloidal systems of a substance in the form of nanospheres. US Patent 5,118,529, 1988.
78. Skiba, M.; Wouessidjewe, D.; Coleman, A.W.; Fessi, H.; Devissaguet, J.-P.; Duchêne, D.; Puisieux, F. Préparation et utilisations de nouveaux systèmes colloïdaux dispersibles à base de cyclodextrines sous forme de nanosphères. French Patent 92 07287, 1992.
79. Skiba, M.; Wouessidjewe, D.; Puisieux, F.; Duchêne, D.; Gulik, A. Characterisation of amphiphilic -cyclodextrin nanospheres. Int. J. Pharm., 1996, 142, 121-124.
80. Gèze, A.; Putaux, J.L.; Choisnard, L.; Jehan, P.; Wouessidjewe, D. Long-term shelf stability of amphiphilic beta-cyclodextrin nanosphere suspensions monitored by dynamic light scattering and cryo-transmission electron microscopy. J. Microencapsul., 2004, 21, 607-613.
81. Memisoglu, E.; Bochot, A.; Ozalp, M.; Sen, M.; Duchêne, D.; Hincal, A.A. Direct formation of nanospheres from amphiphilic - cyclodextrin inclusion complex. Pharm. Res., 2003, 20, 117-125.
82. Memisoglu, E.; Bochot, A.; Sen, M.; Duchêne, D.; Hincal, A.A. Non-surfactant nanospheres of progesterone inclusion complex with amphiphilic -cyclodextrins. Int. J. Pharm., 2003, 251, 143-153.
83. Choisnard, L.; Gèze, A.; Bigan, M.; Putaux, J.L.; Wouessidjewe, D. Efficient size controlled of amphiphilic cyclodextrin nanoparticles through a statistical mixture design methodology. J. Pharm. Pharmaceut. Sci., 2005, 8, 593-600.
84. Thioune, O.; Fessi, H.; Devissaguet, J.-P.; Puisieux, F. Preparation of pseudolatex by nanoprecipitation: influence of the solvent nature on intrinsic viscosity and interaction constant. Int. J. Pharm., 1997, 146, 233-238.
85. Gulik, A.; Delacroix, H.; Wouessidjewe, D.; Skiba, M. Structural properties of several amphiphilic cyclodextrins and some related nanospheres. An X-ray scattering and freeze fracture electron microscopy study, Langmuir, 1998, 14, 1050-1057.
86. Moghimi, S.M.; Hunter, A.C.; Murray, J.C. Long-circulating and target-specific nanoparticles: theory and practice. Pharmacol. Rev., 2001, 53, 283-318.
87. Skiba, M.; Nemati, F.; Puisieux, F.; Duchêne, D.; Wouessidjewe, D. Spontaneous formation of drug-containing amphiphilic - cyclodextrin nanocapsules. Int. J. Pharm., 1996b,126, 241-245.
88. Putaux, J.L.; Gèze, A.; Yaméogo, B.G.J.; Choisnard, L.; Brunet- Manquat, C.; Bakowski, D.; Nishiyama, Y.; Jean, B.; Rochas, C.; Wouessidjewe, D. Ultrastructure of nanoparticles made of amphiphilic cyclodextrins for nanomedicine applications. Proc. 15th European Microscopy Congress, Manchester, United Kingdom, 2012.
89. Lemos-Senna, E.; Wouessidjewe, D.; Lesieur, S.; Duchêne, D. Preparation of amphiphilic cyclodextrin nanospheres using the emulsion solvent evaporation method, influence of the surfactant on preparation and hydrophobic drug loading. Int. J. Pharm., 1998a, 170, 119-128.
90. Quaglia, F.; Ostacolo, L.; Mazzaglia, A.; Villari, V.; Zaccaria, D.; Sciortino, M. The intracellular effects of non-ionic amphiphilic cyclodextrin nanoparticles in the delivery of anticancer drug. Biomaterials, 2009, 30, 374-382.
91. Cannava, C.; Crupi, V.; Ficarra, P.; Guardo, M.; Majolino, D.; Mazzaglia, A.; Stancanelli, R. Physicochemical characterization of an amphiphilic cyclodextrin/genistein complex. J. Pharm. Biomed. Anal., 2010, 51, 1064-1068.
92. Lemos-Senna, E.; Wouessidjewe, D.; Duchêne, D.; Lesieur, S. Amphiphilic cyclodextrin nanoparticles: particle solubilization and reconstitution by the action of a non-ionic detergent. Coll. Surf. B: Biointerfaces, 1998b, 10, 291-301.
93. Zerkoune, L.; Angelova, A.; Choisnard, L.; Gèze, A.; Wouessid- jewe, D.; Lesieur, S. Bioesterified polysubstituted- cyclodextrin/surfactant nanoparticles obtained by multilevel self- assembly. MATEC Web conf., 2013, 4, 05001.
94. Fessi, H.; Devissaguet, J.P.; Puisieux, F. Procédé de préparation de systèmes colloïdaux dispersibles d'une substance sous forme de nanocapsules. French Patent FR 86184444, 1986.
95. Memisoglu, E.; Hincal, A.A. Sterile injectable cyclodextrin nanoparticles: effects of gamma irradiation and autoclaving, Int. J. Pharm., 2006, 311, 203-208.
96. Lemos-Senna, E.; Lesieur, S.; Wouessidjewe, D.; Duchêne, D. Progesterone-loaded in modified cyclodextrin nanoparticles: evaluation of the physical state of the drug. Eur. J. Pharm. Biopharm., 1996, 42(suppl.), 34S.
97. Memisoglu-Bilensoy, E.; Sen, M.; Hincal, A.A. Effect of drug physicochemical properties on in vitro characteristics of amphiphilic cyclodextrin nanospheres and nanocapsules. J. Microen- capsul., 2006a, 23, 59-68.
98. Leroy-Lechat, F.; Wouessidjewe, D.; Puisieux, F.; Duchêne, D. Optimization of entrapment of doxorubicin in nanospheres of modified -cyclodextrin. Ed. Santé Paris, 1994, 463-466.
99. Yaméogo, J.B.G.; Gèze, A.; Choisnard, L.; Putaux, J.L.; Gansané, A.; Sirima, S.B.; Semdé, R.; Wouessidjewe, D. Self-assembled biotransesterified cyclodextrins as Artemisinin nanocarriers - I:Formulation, lyoavailability and in vitro antimalarial activity assessment. Eur. J. Pharm. Biopharm., 2012, 80, 508-517.
100. Skiba, M.; Morvan, C.; Duchêne, D.; Puisieux, F.; Wouessidjewe, D. Evaluation of gastrointestinal behaviour in the rat of amphiphilic -cyclodextrin nanocapsules, loaded with indometacin. Int. J. Pharm., 1995, 126, 275-279.
101. Bilensoy, E.; Gurkaynak, O.; Dogan, A.L.; Hincal, A.A. Safety and efficacy of amphiphilic beta-cyclodextrin nanoparticles for pacli- taxel delivery. Int. J. Pharm., 2008b, 347, 163-170.
102. Vauthier, C.; Bouchemal, K. Methods for the preparation and manufacture of polymeric nanoparticles, Pharm. Res., 2009, 26(5): 1025-1058.
103. Bilati, U.; Allémann, E.; Doelker, E. Nanoprecipitation Versus Emulsion-based Techniques for the Encapsulation of Proteins into Biodegradable Nanoparticles and Process-related Stability Issue. AAPS Pharm.Sci.Tech., 2005, 6, 594-604.
104. Soares, A.; Gèze, A.; Choisnard, L.; Ribuot, C.; Faure, P.; Carvalho, R.A.; Jones, J.G.; Veiga, F.V.; Wouessidjewe D. Enhancement of insulin's action by PLGA-Cyclodextrin esters nanoparticles. Proc. 17th International Conference on Bioencapsulation, Groningen, Netherland 2009.
105. Bilensoy, E.; Gurkaynak, O; Eratn, M.; Sen, M.; Hincal, A.A. Development of nonsurfactant cyclodextrin nanoparticles loaded with anticancer drug paclitaxel. J. Pharm. Sci., 2008a, 97, 1519-1529.
106. Memisoglu-Bilensoy, E.; Vural, I.; Bochot, A.; Renoir, J.M.; Duchêne, D.; Hincal, A.A. Tamoxifen citrate loaded amphiphilic - cyclodextrin nanoparticles: In vitro characterization and cytotoxicity. J. Control. Release, 2005, 347, 489-496.
107. Cirpanli, Y.; Bilensoy, E.; Dogan, A.L.; Calis, S. Comparative evaluation of polymeric and amphiphilic cyclodextrin nanoparticles for effective camptothecin delivery. Eur. J. Pharm. Biopharm., 2009, 73, 82-89.
108. Arnaud, O.; Boumendjel, A.; Gèze, A.; Honorat, M.; Matera, E.L.; Guitton, J.; Stein, W.D.; Bates, S.E.; Falson, P.; Dumontet, C.; Di Pietro, A.; Payen, L. The acridone derivative MBLI-87 sensitizes breast cancer resistance protein-expressing xenografts to irinotecan. Eur. J. Cancer, 2011, 47, 640-648.
109. Memisoglu-Bilensoy, E.; Dogan, A.L.; Hincal, A.A. Cytotoxic evaluation of injectable cyclodextrin nanoparticles. J. Pharm. Pharmacol., 2006b, 58, 585-589.
110. Lahiani-Skiba, M.; Bounoure, F.; Shawky-Tous, S.; Arnaud, P.; Skiba, M. Optimization of entrapment of metronidazole in amphiphilic -cyclodextrin nanospheres. J. Pharm. Biomed. Anal., 2006, 41, 1017-1021.
111. Cirpanli, Y.; Allard, E.; Passirani, C.; Bilensoy, E.; Lemaire, L.; Calis, S.; Benoit, J.P. Antitumoral activity of camptothecin-loaded nanoparticles in 9L rat glioma model. Int. J. Pharm., 2011, 403, 201-206.
112. Goutayer, M.; Dufort, S.; Josserand, V.; Royère, A.; Heinrich, E.; Vinet, F.; Bibette, J.; Coll, J.L.; Texier, I. Tumor targeting of functionalized lipid nanoparticles: assessment by in vivo fluorescence imaging. Eur. J. Pharm. Biopharm., 2010, 75, 137-147.
113. Matsumura, Y.; Maeda, H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic Progress in Developing Amphiphilic Cyclodextrin-Based Nanodevices accumulation of proteins and the antitumor agent smancs. Cancer Res., 1986, 46, 6387-6392.
114. Maeda, H.; Wu, J.; Sawa, T.; Matsumura, Y.; Hori, K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release, 2000, 65, 271-284.
115. Gèze, A.; Tieu Chau, L.; Choisnard, L.; Mathieu, J.P.; Marti-Battle, D.; Riou, L.; Putaux, J.L.; Wouessidjewe, D. Biodistribution of intravenously administrated amphiphilic -cyclodextrin nanospheres. Int. J. Pharm., 2007, 344, 135-142.
116. Hoarau, D.; Delmas, P.; David, S.; Roux, E.; Leroux, J.C. Novel long-circulating lipid nanocapsules. Pharm. Res., 2004, 21, 1783-1789.
117. Vonarbourg, A.; Passirani, C.; Saulnier, P.; Benoit, J.P. Parameters influencing the stealthiness of colloidal drug delivery systems. Biomaterials, 2006, 27, 4356-4373.
118. Moghimi, S.M.; Szebeni, J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Progress Lipid Res., 2003, 42, 463-478.
119. Moghimi, S.M.; Pavey, K.; Hunter, A.C. Real-time evidence of surface modification at polystyrene lattices by poloxamine 908 in the presence of serum: in vivo conversion of macrophage-prone nanoparticles to stealth entities by poloxamine 908. FEBS Lett., 2003, 547, 177-182.
120. Avgoustakis, K.; Beletsi, A.; Panagi, Z.; Klepetsanis, P.; Livaniou, E.; Evangelatos, G.; Ithakissios, D.S. Effect of copolymer composition on the physico-chemical characteristics, in vitro stability, and biodistribution of PLGA-mPEG nanoparticles. Int. J. Pharm., 2003, 259, 115-127.
121. Rodriguez, J.; Santos-Magalhaes, N.; Coelho, L.; Couvreur, P.; Ponchel, G.; Gref, R. Novel core(polyester)-shell(polysaccharide) nanoparticles: protein loading and surface modification with lectins. J. Control. Release, 2003, 92, 103-112.
122. Lemarchand, C.; Gref, R.; Couvreur, P. Polysaccharide-decorated nanoparticles. Eur. J. Pharm. Biopharm., 2004, 58, 327-341.
123. Lemarchand, C.; Gref, R.; Lesieur, S.; Hommel, H.; Vacher, B.; Besheer, A.; Maeder, K.; Couvreur, P. Physico-chemical charac- terization of polysaccharide-coated nanoparticles. J. Control. Release, 2005, 108, 97-111.
124. Béduneau, A.; Saulnier, P.; Anton, N.; Hindré, F.; Passirani, C.; Rajerison, H.; Noiret, N.; Benoit, J.P. Pegylated nanocapsules produced by an organic solvent-Free method: Evaluation of their stealth properties. Pharm. Res., 2006, 23, 2190-2199.
125. Morille, M.; Montier, T.; Legras, P.; Carmoy, N.; Brodin, P.; Pitard, B.; Benoit, J.P.; Passirani, C. Long-circulating DNA lipid nanocapsules as new vector for passive tumor targeting. Biomaterials, 2010, 31, 321-329.
126. Huynh, N.T.; Roger, E.; Lautram, N.; Benoit, J.P.; Passirani, C. The rise and rise of stealth nanocarriers for cancer therapy: passive versus active targeting. Nanomedicine, 2010, 5, 1415-1433.
127. Passirani, C.; Barrat, G.; Devissaguet, J.P; Labarre, D. Interactions of nanoparticles bearing heparin or dextran covalently bound to poly(methyl methacrylate) with the complement system. Life Sci., 1998, 62, 775-785.
128. Vonarbourg, A.; Passirani, C.; Saulnier, P.; Simard, P.; Leroux, J.C.; Benoit, J.P. Evaluation of pegylated lipid nanocapsules versus complement system activation and macrophage uptake. J. Biomed. Mater. Res. A, 2006, 78, 620-628.
129. Moghimi, S.M.; Andersen, A. J.; Ahmadvand, D.; Wibroe, P.P.; Andersen, T.L.; Hunter, A.C. Material properties in complement activation. Adv. Drug Deliv. Rev., 2011, 63, 1000-1007.
130. Harboe, M.; Thorgersen, E.B.; Mollnes, T.E. Advances in assay of complement function and activation. Adv. Drug Deliv. Rev., 2011, 63, 976-987.
131. Texier, I.; Goutayer, M.; Da Silva, A.; Guyon, L.; Djaker, N.; Josserand, V.; Neumann, E.; Bibette, J.; Vinet, F. Cyanine-loaded lipid nanoparticles for improved in vivo fluorescence imaging. J. Biomed. Optics, 2009, 14, 1-11.
132. Dufort, S.; Sancey, L.; Wenk, C.; Josserand, V.; Coll, J.L. Optical small animal imaging in the drug discovery process. Biochim. Biophys. Acta, 2010, 1798, 2266-2273.